882 related articles for article (PubMed ID: 16307657)
1. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
4. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
5. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
6. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
7. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
Daudén E; Griffiths CE; Ortonne JP; Kragballe K; Molta CT; Robertson D; Pedersen R; Estojak J; Boggs R
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1374-82. PubMed ID: 19563497
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
[TBL] [Abstract][Full Text] [Related]
9. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
10. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
[TBL] [Abstract][Full Text] [Related]
13. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
[TBL] [Abstract][Full Text] [Related]
15. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
Luger TA; Barker J; Lambert J; Yang S; Robertson D; Foehl J; Molta CT; Boggs R
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):896-904. PubMed ID: 19453794
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of etanercept as monotherapy for psoriasis.
Gottlieb AB; Matheson RT; Lowe N; Krueger GG; Kang S; Goffe BS; Gaspari AA; Ling M; Weinstein GD; Nayak A; Gordon KB; Zitnik R
Arch Dermatol; 2003 Dec; 139(12):1627-32; discussion 1632. PubMed ID: 14676082
[TBL] [Abstract][Full Text] [Related]
17. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
18. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
Feldman SR; Kimball AB; Krueger GG; Woolley JM; Lalla D; Jahreis A
J Am Acad Dermatol; 2005 Nov; 53(5):887-9. PubMed ID: 16243150
[TBL] [Abstract][Full Text] [Related]
19. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
20. Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
